Vanda Pharmaceuticals Inc. (VNDA) News
Track canonical SquawkNews coverage tagged to VNDA, Vanda Pharmaceuticals Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Vanda reports positive Phase III results for HETLIOZ in DSWPD
EARNINGS | Sep 29, 2026, 10:47 PM UTC
L
Vanda Pharmaceuticals Initiated at Outperform by Oppenheimer
Ratings actions from Benzinga: GMT) Vanda Pharmaceuticals Price Target Announced at $10.00/Share by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:22 PM UTC
L
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead
Five approved products anchor a diversified portfolio, with BYSANTI and NEREUS launches driving near-term growth. Key clinical readouts for MDD and GLP-1-induced nausea could unlock major new markets, while commercial in
NEWS | Sep 15, 2026, 02:49 PM UTC
L
VNDA - Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
VNDA - Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
EQUITY | Sep 02, 2026, 08:52 PM UTC
M
Vanda gets EU orphan designation for imsidolimab in pustular psoriasis
Vanda Pharmaceuticals says the European Commission granted orphan designation for imsidolimab for the treatment of generalized pustular psoriasis.
REGULATION | Aug 24, 2026, 11:01 AM UTC
L
Vanda Pharmaceuticals wins European orphan designation for imsidolimab
Vanda Pharmaceuticals (VNDA) says the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis.
REGULATION | Aug 24, 2026, 11:00 AM UTC
L
VNDA - NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
VNDA - NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
EQUITY | Aug 22, 2026, 07:17 PM UTC
L
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est
Vanda Pharmaceuticals (NASDAQ: VNDA ) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.
EARNINGS | Aug 05, 2026, 08:05 PM UTC
L
VNDA VNDA - Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
VNDA VNDA - Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:02 PM UTC
L
VNDA VNDA - Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
VNDA VNDA - Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
EARNINGS | Jul 29, 2026, 08:32 PM UTC
L
VNDA (more) Vanda Pharmaceuticals - announces EMA positive opinion for orphan drug designation of imsidolimab for gpp
VNDA (more) Vanda Pharmaceuticals - announces EMA positive opinion for orphan drug designation of imsidolimab for gpp
EQUITY | Jul 16, 2026, 08:31 PM UTC
L
VNDA Vanda Pharmaceuticals - imsidolimab BLA for gpp under FDA review with target action date December 12, 2026
VNDA Vanda Pharmaceuticals - imsidolimab BLA for gpp under FDA review with target action date December 12, 2026
REGULATION | Jul 16, 2026, 08:30 PM UTC
L
Vanda Pharmaceuticals Gets FDA Rare Pediatric Disease Designation for CMT2S Therapy
() -- Vanda Pharmaceuticals (VNDA) said Tuesday the Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to VCA-894A, its investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth
REGULATION | Jul 07, 2026, 08:55 PM UTC
L
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
The company states: "Vanda Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-T
EQUITY | Jul 07, 2026, 08:46 PM UTC